Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine whether the addition of aleglitazar versus placebo will reduce a composite outcome of CV death, non-fatal myocardial infarction or non-fatal stroke in patients with stable CVD and glucose abnormalities.
Critère d'inclusion
- - Stable Cardiovascular Disease and
- - Diabetes Mellitus Type 2 or Pre-diabetes